Comparative Pharmacology
Head-to-head clinical analysis: IQIRVO versus LIVDELZI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IQIRVO versus LIVDELZI.
IQIRVO vs LIVDELZI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, reducing the production of the oncometabolite 2-hydroxyglutarate (2-HG) and promoting myeloid differentiation.
LIVDELZI is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It binds to and activates PPARα, which regulates the expression of genes involved in lipid metabolism, reducing hepatic fat accumulation and improving steatohepatitis.
For NBNC (non-B, non-C) hepatocellular carcinoma with no prior systemic therapy: 110 mg orally once daily with or without food.
80 mg intravenously once daily infused over 1 hour.
None Documented
None Documented
Terminal half-life is approximately 24 hours, supporting once-daily dosing.
Terminal elimination half-life approximately 26–32 hours in patients with primary biliary cholangitis; supports once-daily dosing.
Primarily biliary/fecal excretion with minimal renal elimination (<5%).
Primarily biliary excretion (≥70% of absorbed dose) as unchanged drug and metabolites; renal excretion accounts for <5%.
Category C
Category C
PPAR Agonist
PPAR Agonist